肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Erratum: Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
[本文更正文章 DOI: 10.1016/j.omton.2024.200820。]
In vitro characterization of a novel anti-GD2/ROR1 bispecific antibody exhibiting tumor cell killing efficacy in neuroblastoma cross-cancer activity i
G/R-001 BsAb可同时结合GD2和ROR1，并在体外显示出显著的抗肿瘤活性。这些结果为G/R-001作为新型抗肿瘤治疗药物的进一步开发提供了有力的实验证据。
Combinatorial immunotherapy with anti-ROR1 CAR NK cells and an IL-21 secreting oncolytic virus against neuroblastoma.
我们的结果表明，分泌细胞因子的溶瘤病毒联合CAR-NK细胞是一种治疗高危NB的新型有效免疫治疗方法。
Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts.
在体内，与单用 anti-ROR1 CAR exPBNK 相比，anti-ROR1 CAR exPBNK 联合 N-803 显著（p < 0.05）提高了人 ROR1⁺ NB 异种移植 NSG 小鼠的生存率。
MEMBER ACCOUNT
登录成功会直接打开下一页。
